community it serves. The study was approved by the Henry Ford Health System institutional review board. Because the study examined patient medical records only, the review board waived the need to obtain patient consent.
Sociodemographic, exposure, and clinicopathologic data, including comorbidity data, were abstracted directly from medical records. Treatment data included surgery, chemotherapy, radiation, and hormone therapy as dichotomous variables (received or not). Additionally, information on type of surgery was collected. For chemotherapy and radiation therapy, data were not available on treatment completion or dose reduction. Survival and causeof-death data were obtained from the Henry Ford Health System and Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) tumor registries and from Michigan Department of Vital Statistics death certificate data. The last date of follow-up was May 1, 2002 .
Data on failure to control cancer, either as local recurrence following resection or progression reflected in local expansion or regional or distant spread of cancer, were abstracted from medical records. Socioeconomic status was estimated by area-based socioeconomic measures taken from patients' addresses and 1990 census data at the block group level, and included median household income, proportion living below poverty level, and proportion not completing high school. Race was classified according to selfreport on registration forms. Analysis was limited to blacks and whites; Asians, Pacific Islanders, Native Americans, and others were excluded because the numbers were too small to permit meaningful analysis. There were only 4 patients who were identified as Hispanic and they were included in the analysis according to the race category they chose (3 white, 1 black).
Comorbidity data were abstracted directly from medical records from 3 years prior to breast cancer diagnosis up until first breast cancer treatment or 6 months following diagnosis if no treatment was administered. In this study, all comorbidity data were collected and coded into 259 essentially mutually exclusive diagnostic categories of the Clinical Classification Software, 25 developed by the US Agency for Healthcare Research and Quality to facilitate health research by producing a manageable number of clinically meaningful disease categories from the more than 12 000 codes in the International Classification of Diseases, 9th Revision, Clinical Modifications text. 26 This comorbidity list was supplemented by comorbidities suggested to be important in our previous studies of comorbidity and lung cancer outcomes 27,28 to yield 268 comorbidities in 16 comorbidity categories.
This study focuses on the impact of adverse comorbidities on outcomes, with adverse comorbidities being defined as those that had significantly elevated Cox regression hazard ratios (all-cause survival) regardless of effect magnitudes, that had hazard ratios (HRs) greater than 1.20 regardless of statistical significance, or that were deemed to be adverse a priori based on clinical knowledge and/or past research (eg, HIV/ AIDS). Seventy-seven comorbidities were classified as adverse (TABLE 1) and in this report mention of comorbidity refers specifically to these 77 comorbidities. The abstraction form and table of HRs and racial distributions for comorbidities are available online at http: //www.brocku.ca/communhealthsci /jama. To facilitate interpretation of effect estimates and to evaluate doseresponse relationships, comorbidity counts were divided into approximate quintiles of comparable size.
For comparative purposes the Charlson Comorbidity Index 29 was evaluated. The index was developed using hospital emergency department admissions with 1-year mortality as the outcome and was validated in breast cancer patients. It is computed by weighting and summing 19 comorbidities. Of all comorbidity indices to date, the Charlson has been most extensively studied and has been deemed to be a valid and reliable method of measuring comorbidity for clinical research. 30 Cancer stage, based on pathological stage and in its absence on clinical stage, was analyzed according to the American Joint Committee on Cancer TNM staging system. 31 Histotype was based on World Health Organization categories. 32
Statistical Analysis
Contingency table analyses were carried out and null hypotheses were evaluated using the Fisher exact test and nonparametric tests for trend 33 when applied to ordinal data. Logistic regression odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate associations between predictors and dichotomous outcomes.
Univariate and multivariate survival analyses were carried out using Kaplan-Meier, life table, and Cox proportional hazards regression analyses. 34, 35 Modeling proceeded from univariate to multivariate and preparation of parsimonious multivariable models was guided by a priori considerations 36 and was aided by backward stepwise elimination. Death was considered to be breast cancer-specific if either the SEER Registry or Michigan death certificate data indicated the cause of death was breast cancer. Classification of survival status into the categories alive, breast cancer death, or competing causes of death in the 2 registries had 91.9% agreement. Where cause of death data were present in both registries agreement was high: the statistic 37 was 0.98 (lower confidence limit, 0.80) for blacks and 0.96 (lower confidence limit, 0.83) for whites.
When death due to competing causes was analyzed, breast cancer-specific deaths were censored. The reversecensoring Kaplan-Meier method, which eliminates bias introduced by differential death rates, was used to compare follow-up between groups. 38 The c statistic was used to measure the predictive ability of Cox models. 39 The c statistic is analogous to the area under the receiver operating characteristic curve and can be thought of as follows: con-sidering all possible combinations of paired individuals under study with differing survival times, the c statistic represents the proportion for which the regression model correctly predicts the survival order. 39, 40 The amount of racial survival disparity explained by comorbidity was estimated by the proportion decline in HR, black vs white, comparing the comorbidity-adjusted with the unadjusted model.
In survival regression analysis, proportional hazard assumptions were tested graphically and statistically and were met for all presented models. In logistic regression analysis, modeling of collinear variables was avoided, regression diagnostics were carried out, and conventional diagnostic standards were met for all models presented. In multivariate models interaction terms were considered. The ␣ error was set at .05 and all reported P values, except for the statistic, are 2-sided. Stata version 7.0 software (Stata Corporation, College Station, Tex) was used to prepare statistics.
RESULTS
Through the tumor registry, 924 individuals were identified as having breast cancer. Analyses were restricted to the 906 individuals who were black (n = 264, 29.1%) or white (n = 642, 70.9%). Follow-up data were missing for 7 blacks (2.7%) and 13 whites (2.0%) (P=.62). Of 886 individuals for whom survival data were available, loss to follow-up occurred prior to 10 years in 56 individuals (6.3%). Cox regression analysis demonstrated that time to loss to follow-up was associated with younger age (HR per 10 years, 0.62; 95% CI, 0.52-0.74) but not with race or comorbidity; adjusted for age, the HR for loss to follow-up for race was 0.63 (95% CI, 0.29-1.37) and the HR for co- 
Survival Data
Overall, the median follow-up was 10.0 years (range, 0.04-17.8 years). Of those who survived, median follow-up did not differ significantly between blacks (12.8 years) and whites (12.7 years), indicating comparable follow-up data quality. A total of 159 blacks (61.9%) and 317 whites (50.4%) died (P=.002) ( 
Comorbidity and Survival
For those with comorbidity data, 28.3% had no comorbidities. Patients had a mean of 2.02 (median, 1; range, 0-13) comorbidities. The univariate HR for comorbidity count as a single 5-level variable (0, 1, 2, 3, and 4-13 comorbidities) was 1.40 (95% CI, 1.31-1.49). Following adjustment for age, tu- mor stage, estrogen receptor positivity, surgery, chemotherapy, and radiation therapy, the HR for comorbidity count (5-level) was 1.29 (95% CI, 1.19-1.40). A dose-response relationship was indicated by a monotonic increase in HRs with increasing numbers of comorbidities (TABLE 3 and FIGURE 1) . The effect of comorbidity on survival did not differ by age; the comorbidityϫage interaction P value was .46.
Comorbidity and Disparity in All-Cause Survival
Compared with whites, blacks had shorter overall survival (HR,1.34; 95% CI, 1.11-1.62; FIGURE 2). One or more comorbidities were reported in 221 blacks (86%) and 407 whites (65.7%) (OR,3.20; 95% CI, 2.17-4.72). The distributions of comorbidities by race are presented in Table 2 and FIGURE 3. Comorbidity count evaluated as a single 5-level variable explained 49.1% of the racial disparity in overall survival (comorbidity-adjusted HR, 1.17; 95% CI, 0.96-1.43 (TABLE 4) . Adjusted for age, tumor stage, estrogen receptor status, surgery, chemotherapy, and radiation therapy, the HR for black vs white was 1.14 (95% CI, 0.92-1.40), and when additionally adjusted for comorbidity count (5 levels) the HR was 1.02 (95% CI, 0.83-1.27). These data indicate that comorbidity explains disparity in allcause survival in addition to other prognostic factors. The effect of comorbidity on survival did not differ by race (P value for interaction = .99).
A total of 280 patients (30.9%) were older than 70 years. Racial disparity in survival was evident in patients younger than 70 years (HR,1.23; 95% CI, 0.94-1.61) and in those 70 years or older (HR, 1.25; 95% CI, 0.95-1.65). The effect of race on all-cause survival did not differ by age (P for interaction =.89). In the group aged younger than 70 years, at least 1 comorbidity was present in 78.7% of blacks and 56.9% of whites (PϽ.001); in the group aged 70 years or older, at least 1 comorbidity was present in 97.1% of blacks and 89.3% of whites (P =.02). Adjusted for comorbidities, the HR for black vs white was 1.13 (95% CI, 0.85-1.50) in the younger group and 1.18 (95% CI, 0.89-1.57) in the older group, declines of 43.4% and 27.0%, respectively.
We also evaluated the impacts of all specific comorbidities with elevated frequencies in blacks compared with whites. Two of the most important comorbidities explaining survival disparity were diabetes and hypertension. The HR associated with diabetes was 1.85 (95% CI, 1.47-2.32) and the prevalence of diabetes in blacks and whites was 68 (26.4%) and 59 (9.5%), respectively (OR for black vs white, 3.41; 95% CI, 2.32-5.02). The HR associated with hypertension was 1.65 (95% CI, 1.37-1.99) and the prevalence of hypertension in blacks and whites was 163 (63.4%) and 220 (35.5%), respectively (OR, 3.14; 95% CI, 2.32-4.26). Adjusted for these 2 comorbidities, the HR for black vs white was 1.09 (95% CI, 0.89-1.35), a decline of 72.4% from the unadjusted estimate. Most of the complications of diabetes and hypertension that led to patient deaths developed well after the breast cancer di-agnosis and outside the record abstraction period, and thus these data were unavailable for analysis. At the time of diagnosis, 8 black (3.1%) and 7 white (1.1%) patients (OR, 2.81, 95% CI, 1.01-7.83) had diabetic complications, which included circulatory problems, retinopathy, neuropathy, and ketoacidosis in both groups. Coronary disease occurred in 31 blacks (12.1%) and 51 whites (8.2%) (OR,1.53; 95% CI, 0.95-2.45) and was associated with increased hazard (HR,1.78; 95% CI, 1. 35-2.35 ).
Comorbidity and Disparity in Progression/Recurrence and Breast Cancer-Specific Survival
Blacks had significantly more breast cancer recurrence/progression than did whites (35.8% vs 27.6%; OR, 1.47; 95% 1  147  114  21  84  2  97  64  2  43  3  162  76  5  40  4-13 The study comorbidities are detailed in Table 1 .
RACIAL DISPARITIES IN BREAST CANCER SURVIVAL
©2005 American Medical Association. All rights reserved. CI, 1.06-2.03). Breast cancer recurrence/progression was strongly predictive of reduced breast cancer-specific survival (HR, 24.40; 95% CI, 15. 41-38.62 ) and compared with whites, blacks experienced shorter breast cancer-specific survival (HR, 1.47; 95% CI, 1.08-2.00). Comorbidity (5 levels) was not associated with breast cancer recurrence/progression (OR, 0.98; 95% CI, 0.88-1.08) or with breast cancerspecific survival (HR, 1.01; 95% CI, 0.91-1.12) and did not explain racial disparity in recurrence/progression or breast cancer-specific survival. Adjusted for comorbidities (5 levels), the recurrence/progression OR for black vs white was 1.47 (95% CI, 1.06-2.03) and breast cancer-specific HR was 1.50 (95% CI, 1.09-2.05).
Comorbidity may lead to breast cancer recurrence/progression and re-duced breast cancer−specific survival by causing less aggressive or no treatment. The single most protective cancer treatment was surgery (HR, 0.29; 95% CI, 0.17-0.50), and comorbidity (5 levels) predicted nonreceipt of surgery (OR, 0.72, 95% CI, 0.58-0.88). Adjusted for marital status, SES (block group poverty level), and tumor stage, comorbidity remained predictive of nonreceipt of surgery (OR, 0.71; 95% CI, 0.54-0.91). In univariate analysis age was associated with nonreceipt of surgery (OR per 10 years, 0.70; 95% CI, 0.55-0.89). Age and comorbidity were collinear (OR for Ն1 vs 0 comorbidity per 10 years, 2.37; 95% CI, 2.06-2.71) and in multivariate analysis comorbidity was more predictive of surgery than age was. However, in this study population, regardless of the higher frequency of comorbidities in blacks, similarly high proportions underwent surgery: 239 blacks (94.1%) and 584 whites (95.6%) (P=.39). This latter observation in part explains why comorbidity did not account for the racial disparity in recurrence/progression and breast cancer−specific survival.
Comorbidity and Disparity in Competing-Causes Survival
For competing-causes survival, the HR for black vs white was 1.27 (95% CI, 1.00-1.63) and for comorbidity (5 levels) the HR was 1.69 (95% CI, 1.55-1.84). Adjusted for comorbidity, the HR for black vs white was 1.06 (95% CI, 0.83-1.36), a decline of 76.7% from the unadjusted analysis (Table 4) .
Body mass index (calculated as weight in kilograms divided by height in meters squared) of 25 or higher (ie, overweight) was observed in 72% of blacks and 49.7% of whites (PϽ.001) and had the greatest impact on competing-causes survival. Compared with a BMI of 18.5 to less than 25, the univariate HRs (competing-causes survival) for BMI were as follows: for BMI of 25 to less than 30: 1.12 (95% CI, 0.84-1.50); for BMI of 30 to less than 35: 1.16 (95% CI, 0.81-1.65); and for BMI of 35 or higher: 1.35 (95% CI, 0.91-2.00). Adjusted for diabetes, hyperten- Abbreviation: CI, confidence interval. *Study comorbidities and the Charlson index were modeled as 5-level variables: 0, 1, 2, 3, and 4-13 and 0, 1, 2, 3, and 4-9, respectively. †Hazard ratio modeled as a single 5-level variable; estimate is for 1 level of change (of possible 5). ‡Compared with the unadjusted hazard ratio = 1.34 (95% CI, 1.11-1.62). §Compared with the unadjusted hazard ratio = 1.28 (95% CI, 1.00-1.63). sion, or comorbidity, all of these HRs approached the null, suggesting that adverse effects of obesity are mediated through comorbidity. Low BMI carried significant risk (HR for Յ18.5 vs Ͼ18.5 to Ͻ25, 2.34; 95% CI, 1.22-4.50). However, low BMI occurred less frequently in blacks than in whites (0.8% vs 4.0%, P = .02) and did not explain disparity in competing-causes or breast cancer-specific survival (low BMI-adjusted HR for black vs white, 1.26; 95% CI, 0.98-1.63 and HR, 1.49; 95% CI, 1.07-2.07, respectively).
Comorbidity Measurement
In the current study, comorbidity was an important predictor of survival and explained important amounts of survival disparity. Comorbidity is complex and optimal measurement methods that are robust across different outcomes and populations have not been established. Our study comorbidities demonstrated criterion (concurrent) validity 41 because they correlated well with the established C h a r l s o n C o m o r b i d i t y I n d e x (r 2 = 0.47, PϽ.001). Charlson index score greater than 0 occurred in 51.7% of blacks and 40.4% of whites (P for trend=.002) ( Table 2 ). The Charlson index demonstrated a dose response with all-cause survival ( Table 3) . Table 4 presents a comparison of the ability of the study comorbidities and Charlson index to predict survival to all-cause and competing-causes death and explain disparity in these outcomes. The predictive ability as measured by the c statistic for both outcomes was consistently greater for study comorbidities than for the Charlson index, and this held true whether comorbidity was modeled as a single 5-level variable or multiple categorical variables. Similarly, the study comorbidities explained more survival disparity for all-cause and competing-causes survival ( Table 4 ). These statistics suggest that the Charlson index failed to capture some relevant information present in the study comorbidities, which were based on a more extensive comorbidity inventory.
COMMENT
The current study found that black breast cancer patients have more cancer recurrence/progression and worse all-cause, breast cancer-specific, and competing-causes survival. Comorbidity explained approximately half of the overall survival disparity and the majority of competing-causes survival disparity, which accounted for the preponderance of deaths in black patients. Comorbidity was not associated with recurrence/progression or breast cancer-specific survival.
As in the current study, Eley et al 5 found that comorbidity was an important independent predictor of all-cause survival but not of breast cancer-specific survival, was significantly more frequent in blacks, and explained 25% of all-cause survival disparity (vs 49% in this study). Eley and colleagues considered only 6 categories of comorbidity and their comorbidity frequencies were substantially below those observed in our study, suggesting that their comorbidity adjustment may have been incomplete. Additionally, their follow-up was shorter than in the current study, which led to a heavier weighting of breast cancer vs competing-causes deaths, thus underemphasizing the impact of comorbidity on overall survival.
Analysis of all-cause survival may seem superfluous following analysis of breast cancer-specific and competingcauses survival. However, the misclassification that can occur between the latter 2 categories does not occur with allcause death. Also, all-cause survival to some extent captures combined effects, because it is likely that in some cases comorbidity and breast cancer are not mutually exclusive but in combination contribute to shortened survival. Thus, survival to all-cause death serves as a useful outcome for summarizing the overall impact of comorbidity on the study cohort.
Optimal methods for comorbidity measurement are under development. The Charlson Comorbidity Index was validated, that is, found to significantly predict survival in breast cancer patients, and has been shown to be comparably predictive in black and white breast cancer patients. 42 However, demonstration of significant association with survival does not alone indicate that a measure has high content validity and that it is optimized for studying disparities. Our previous study of comorbidity and lung cancer survival found that infrequent comorbidities in aggregate had an important impact on survival, that the Charlson index omitted several important predictive comorbidities, that the Charlson index's weighting scheme did not correspond to HRs for several comorbidities, and that the Charlson index's explanatory ability was at par with count of any comorbidity. 27 Similarly, this study's findings suggest that the Charlson index might not be an optimal scale for studies of breast cancer survival and disparity. The current data set served as a test/validation set for the Charlson index, whereas it was the training set for the current study's comorbidity inventory. However, study comorbidities appeared to be consistently better than the Charlson index in predicting survival and explaining disparity, even though no weighting of comorbidity effects was applied.
The current study had design features that overcame limitations of some earlier studies. It included a relatively large, single-institution cohort of breast cancer patients with a relatively lengthy follow-up. Comorbidity data were collected systematically in detail from medical records, which are generally considered superior to data collected from administrative databases. [43] [44] [45] [46] Although cancer treatment was controlled for in the analysis, data indicate that treatment differences were not important in leading to survival disparity within this health care system. This report presents surgery as a dichotomous variable. Specific types of surgery (eg, lumpectomy, mastectomy) were also analyzed but did not explain survival or disparity beyond the binary surgery variable (data not shown). The generalizability of our study findings to other populations needs to be established through fur-ther investigation. Important factors that impede access to quality health care were not evaluated in this analysis but must be considered in overall understanding of disparity.
Our findings indicate that control of comorbidity may be an important way of improving the survival of black breast cancer patients and reducing racial disparity. That comorbidity explained more than 40% of the survival disparity in patients younger than 70 years indicates that effective management of comorbidity has the potential to lead to a substantial increase in person-years of life gained. Control of just 2 comorbidities, diabetes and hypertension, could have a major beneficial impact.
